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Amaranth is an ancestral crop used by pre-Columbian cultures for 6000 to 8000 years. Its
grains have a relevant chemical composition not only from a nutritional point of view but
also due to the contribution of components with good techno-functional properties and
important potential as bioactive compounds. Numerous studies have shown that
amaranth storage proteins possess encrypted sequences that, once released, exhibit
different physiological activities. One of the most studied is antihypertensive activity. This
review summarizes the progress made over the last years (2008–2020) related to this
topic. Studies related to inhibition of different enzymes of the Renin-Angiotensin-
Aldosterone system, in particular Angiotensin Converting Enzyme (ACE) and Renin, as
well as those referring to potential modulation mechanisms of tissue or local Renin-
Angiotensin-Aldosterone system, are analyzed, including in silico, in vitro, in vivo, and ex
vivo assays. Furthermore, the potential use of these bioactive peptides or products
containing them, in the elaboration of functional food matrices is discussed. Finally, the
most relevant conclusions and future requirements in research and development of food
products are presented.
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Amaranth is a pseudocereal that was part of the diet of pre-Columbian cultures. The diet of Aztecs,
Mayas, and Incas was mainly based on plant foods, which were low in fat, with moderate protein
content and rich in complex carbohydrates. Maya were the first culture to domesticate amaranth
about 5000 to 7000 years ago, and to use it as a high-yield crop consumed by all social classes
(Bressani, 2003; Montúfar, 2016).
Amaranth grains contain more proteins, lipids, and minerals than many other cereals. The most
abundant component, in dry base (d.b) is starch (60–72%), followed by protein (15–19%), lipids (7–
8%), dietary fiber (8–16%), and minerals (3–5%). The starch fraction presents a high amylopectin
content, the protein fraction has high digestibility (90%) and biological value (86%), the lipid
fraction contains unsaturated fatty acids (25:75 saturated:unsaturated) and an unsaponifiable
tocopherols and squalene rich fraction, the fiber fraction is rich in xyloglucans and pectic
polysaccharides. Amaranth also presents a high percentage of insoluble fiber (78%) and minerals
such as copper, manganese, iron, zinc, magnesium, calcium, phosphorus, and potassium. The
content of these minerals is higher than that found in rice and corn (Stone and Lorenz, 1984;.org September 2020 | Volume 11 | Article 5786311
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2013; Lamothe et al., 2015; D’Amico and Schoenlechner, 2017;
Velarde-Salcedo et al., 2018). The polyphenolic fraction that
contains considerable amounts of rutin, isoquercetin, and
nicotiflorine is also important (Venskutonis and Kraujalis,
2013; D’Amico and Schoenlechner, 2017). This composition is
unique and attractive not only from the nutritional point of view
but also as a source of components with good techno-functional
properties and enormous potential as bioactive compounds.
Seed proteins are classified as albumins, globulins, glutelins,
and prolamines and they determine the structural and
physicochemical characteristics of concentrates and isolated.
Amaranth proteins have been extensively studied. Globulins,
which is the most important fraction, contains 11S and 7S
globulins (11S-glob and 7S-glob), as found in other grains
(Barba de la Rosa et al., 1996; Martıńez et al., 1997; Marcone
and Kakuda, 1999; Osuna-Castro et al., 2000; Gorinstein et al.,
2001; Quiroga et al., 2010; Quiroga et al., 2012; Tandang-Silvas
et al., 2012). Martıńez and Añón (1996) have proposed a third
fraction, globulin P (P-glob), which is solubilized in water after
the extraction of the 11S-glob and 7S-glob in saline solution. The
P-glob fraction had previously been identified by Konishi et al.
(1991) who had named it albumin-2. P-glob is composed of
unitary molecules of molecular weight and polypeptide
composition similar to those of 11S-glob and aggregates larger
than 500 kDa. It also contains a 56 kDa distinctive polypeptide
(an unprocessed subunit), which is involved in the polymer
stabilization (Martıńez and Añón, 1996; Martıńez et al., 1997;
Molina et al., 2008). These features make P-glob a hallmark of
amaranth. Besides, P-glob has a less compact and more
hydrophobic structure than that of 11S-glob; it is thermostable
and presents a high degree of polymerization (Castellani et al.,
1999; Castellani et al., 2000).
According to Quiroga et al. (2007, 2009); 11S-glob and P-glob
would be two 11S-glob isoforms formed by polypeptides
encoded by two different legumin gene subfamilies. Velarde-
Salcedo et al. (2018) have recently suggested that amaranth
glutelins could be polymerized globulins.
Different studies have shown that amaranth proteins, as
protein isolates or isolated fractions, have good gelling,
foaming and emulsifying capacities and presents good
solubility at acidic and alkaline pH (Cordero-de-los-Santos
et al., 2005; Avanza et al., 2006; Bejarano-Luján et al., 2010;
Ventureira et al., 2012; Bolontrade et al., 2013; Tapia-Blácido
et al., 2013; Condés et al., 2013; Shevkani et al., 2014a; Shevkani
et al., 2014b; Bolontrade et al., 2016; López et al., 2018; Suarez
and Añón, 2018). On the other hand, it has recently
been demonstrated that amaranth storage proteins, like
other proteins of plant and animal origin, have encrypted amino
acid sequences displaying different physiological activities:
antihypertensive, antioxidant, antiproliferative/antitumor,
antithrombotic, antihaemolitic, antimicrobial, hypocholesterolemic,
hypoglycemic, and immunomodulatory. These sequences can be
released by enzymatic treatment, through fermentative processes
or during the gastrointestinal digestion (Barrio and Añón, 2010;
Lado et al., 2015; Sabbione et al., 2016a; Sabbione et al., 2016b;Frontiers in Plant Science | www.frontiersin.org 2Moronta et al., 2016a; Moronta et al., 2016b; Orsini Delgado
et al., 2016; Garcıá Fillerıá and Tironi, 2017; Quiroga et al., 2017;
Orona-Tamayo et al., 2019; Martinez-Lopez et al., 2020; Nardo
et al., 2020; Suárez et al., 2020).
Bifunctionality (technological and biological) and nutritional
properties make amaranth a promising and very interesting
source for the formulation of functional foods.BIOACTIVE PEPTIDES AS BLOOD
PRESSURE REGULATORS
Cardiovascular diseases (CVD) are one of the most important
chronic non-communicable diseases and one of the leading
causes of death in the world, even doubling those corresponding
to cancer (WHO, 2016). The main risk factor for CVD is
hypertension, which is responsible for 45% of heart attacks and
51% of strokes (WHO, 2018).
Pharmaceutical industry has developed different medications
to control hypertension; some of them act on components of the
Renin-Angiotensin-Aldosterone system. Among these drugs are
angiotensin converting enzyme (ACE) and renin inhibitors,
angiotensin II Type-1 receptor (AT1 receptor) blockers,
calcium channel blockers, alpha and beta-blockers, diuretics,
and vasodilators. An interesting alternative therapy is to
control blood pressure (BP) by means of diets, including the
consumption of functional foods, thus reducing the risk of
developing non-communicable diseases, such as cardiovascular
diseases. Although there are different components present in
foods with proven functional or physiological activity, bioactive
peptides have become relevant in recent years.
Particularly, antihypertensive peptides have been found and
characterized in animal and vegetable proteins from different
food sources (milk, fish, meat, eggs, and different vegetables,
among others). Most of them are ACE inhibitors although, renin
inhibitors and NO production activators have been described
(Hernández-Ledesma et al., 2011; Martıńez-Maqueda et al.,
2012; Hernández-Ledesma et al., 2013; He et al., 2014; Aluko,
2015a; Saleh et al., 2016; Borghi and Cicero, 2017; Cicero and
Colletti, 2017). Among different food sources of antihypertensive
peptides, dairy proteins are the most studied including trials in
humans (Cadée et al., 2007; Martıńez-Maqueda et al., 2012).
Besides, commercial antihypertensive products have been
developed as Peptide C12 which contains a casein-derived
peptide with sequence FFVAPFPGVFGK, this peptide reduces
BP in pre-hypertensive people (Cadée et al., 2007).
Due to the worldwide relevance of CDV and the possibility of
using bioactive peptides as an alternative and complementary
therapy, it is important to deepen our understanding of the blood
pressure control system in humans.
RAAS System
The Renin-Angiotensin-Aldosterone system, RAAS, is a complex
dual system acting at systemic and local levels (Figure 1). The
Classic circulating RAAS plays a role in the regulation ofSeptember 2020 | Volume 11 | Article 578631
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maintenance of BP and fluid balance. The Tissue/local RAAS
is present in several organs, the lymphatic system, the adipose
tissue, and blood vessels. These tissues can synthetize the
components of the circulating RAAS and form Ang II
independently from the circulating system (Carey and Siragy,
2003; Nguyen Dinh Cat and Touyz, 2011; Zhuo et al., 2013).
In the RAAS, Ang II is formed from angiotensinogen (Agt) by
the action of two enzymes, renin (Inagami, 1981) and ACE
(Corvol et al., 2004; Zhuo et al., 2013). Agt is transformed into
angiotensin I (Ang I), which is rapidly converted to Ang II. Ang
II is a potent vasoconstrictor that acts on vascular cells of the
smooth muscle through its binding to the AT1 receptor but it
also interacts with the angiotensin II type 2 receptor (AT2
receptor) decreasing BP (Unger et al., 1996; de Gasparo et al.,
2000). As well Ang II increases sodium reabsorption and
stimulates the aldosterone and vasopressin production (Touyz
and Schiffrin, 2000).
Ang II, via AT1 receptors, acts on the endothelium, whose
activity is regulated by the cellular redox state (Oskarsson and
Heistad, 1997; Jiang et al., 2008). High levels of Ang II lead to
oxidative stress and a decrease of NO through the activation of
the NADPH/NADH oxidase. This leads to inflammation and cell
growth. Ang II also stimulates the release of endothelin-1 (ENT-
1), which is a potent vasoconstrictor (Pérez et al., 2003).
More recent studies assessing the local RAAS have identified
new components and mechanisms, some of which contribute to
the natriuretic/vasodilator effects of the system by opposing the
effects of Ang II (Carey and Siragy, 2003; Zhuo et al., 2013).
Different peptidases transform Ang II in less potent or inactive
peptides, Ang III and in a Ang IV (Padia et al., 2006). Ang IV
binds to the AT4 receptor, which is expressed in different tissuesFrontiers in Plant Science | www.frontiersin.org 3and exerts different actions as increasing the renal cortical blood
flow, the tubular reabsorption of Na+ and natriuresis (Handa
et al., 1998; Albiston et al., 2001).
Ang II is also hydrolyzed by ACE2, which hydrolyzes Ang I,
but to a lesser extent (Donoghue et al., 2000; Turner et al., 2002;
Hamming et al., 2007). The product of this hydrolysis is Ang 1-7,
an heptapeptide with vasodilator capacity that binds to theMas-
1 receptor (Ferrario et al., 1991; Santos et al., 2003; Kostenis
et al., 2005; Santos et al., 2013). The hydrolysis of Ang I can in
turn generate Ang 1-7 by the action of neutral tissue
endopeptidases, NEP 24.11, 24.15 and 24.26, or it can be
converted into Ang 1-9, which is then converted into Ang 1-7
by ACE (Yamamoto et al., 1992; Vickers et al., 2002; Ferrario,
2006; Zhuo et al., 2013).
A specific receptor for renin and prorenin (PRR) has been
detected in different tissues. PRR would exert Ang II-dependent
and independent effects (Nguyen, 2007; Advani et al., 2009).
New insights into the RAAS system have provided novel
targets to control BP, particularly through the inhibition of key
enzymes, receptor or other mechanisms.
Antihypertensive Peptides in Amaranth
Seeds
The first studies related to the existence of bioactive peptides
encrypted in amaranth storage proteins date to a decade ago.
Since then, different types of in vitro, in vivo, ex vivo and in silico
tests have been carried out, which have allowed obtaining
additional information and building a still incomplete painting.
ACE - Inhibitory Peptides
ACE is one of the main targets in the search for peptides with
antihypertensive activity, either as a replacement or as aFIGURE 1 | Sites of action of amaranth peptides in the circulating and local RAAS system. Agt: angiotensinogen; Ang I, II, III, IV, (1-9), (1-7): angiotensin I, II, III, IV,
(1-9) and (1-7); ACE: angiotensin converting enzyme; APA, APN, and APD: aminopeptidases A, N, and P; PEN: neutral peptidases. Mas-1: Mas-1 receptor, AT1:
angiotensin II type1 receptor, AT2: angiotensin II type 2 receptor, AT3: angiotensin III receptor AT4: angiotensin IV receptor. BK-B2: bradykinin B2 receptor.September 2020 | Volume 11 | Article 578631
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membrane-bound dicarboxypeptidase that requires Zn++ and Cl-
as cofactors. This enzyme exists in two isoforms: the somatic
enzyme (ACEs) and the testicular enzyme (ACEt). Two forms of
the somatic enzyme can be identified, the tissue and the soluble
forms. ACEs is the main producer of Ang II and is expressed in
most human tissues including vascular endothelial cells. It is a
highly glycosylated protein with two metalloproteinase domains, N-
and C-, each containing a catalytic site with the canonical Zn2+
binding motif HEXXH (Watermeyer et al., 2009; Bernstein
et al., 2013).
ACE catalyzes the conversion of the Ang I decapeptide
(DRVYIHPFHL) into a potent vasoconstrictor, Ang II, by the
removal of the two C-terminal amino acids. Although Ang I has
the same affinity for both catalytic sites, the generation of Ang II
is mainly accomplished by the C-domain. The catalytic efficiency
of the C-domain is three times higher than that of N- domain
(Van Esch et al., 2005; Fuchs et al., 2008; Masuyer et al., 2012).
ACE is also part of the kinin-kallikrein system that degrades the
potent vasodilator bradykinin to yield inactive fragments. The latter
reaction is catalyzed equally efficiently by both the C- and the N-
domain (Corvol et al., 2004). These evidences clearly indicate that
each domain presents substrate specificity. Therefore, to accomplish
the inhibition of ACE, peptides capable of specifically interacting
with the C- domain are required.
These results clearly indicate that the hydrolytic activity of
each domain has substrate specificity. Therefore, if one wishes to
inhibit ACE, one should look for peptides capable of specificallyFrontiers in Plant Science | www.frontiersin.org 4interacting with the C-domain of the enzyme and/causing
binding of conformational changes at the active site leading to
a lack or decrease of recognition of the natural substrate.
In the particular case of amaranth, numerous studies have
been carried out which will be discussed depending on the type
of analysis performed.
In Silico Assays
In silico studies carried out by Silva-Sánchez et al. (2008) have
demonstrated for the first time the existence of different bioactive
peptides in amaranth storage proteins. The search for bioactive
peptides was done by exploring two databases, one
corresponding to the amaranth protein sequence (www.ncbi.
nlm.nih.gov) and the other comprising existing bioactive
peptides (actually BIOPEP-UWM, http://www.uwm.edu.pl/
biochemia/index.php/pl/biopep). Of the twelve potential
activities detected (activating ubiquitin mediated proteolysis,
antiamnestic, antihypertensive, antioxidant, antithrombotic,
embryotoxic, immunomodulating, immunostimulating, ligand,
opioid, regulating, protease inhibiting), antihypertensive one was
the most frequent in 11S-glob protein. Using the same type of
analysis, it was located in the sequence of this protein di and
tripeptides, five of which (GKP, LF, YL, RF, and HY) according
to the literature were ACE inhibitors (Table 1).
Using bioinformatics tools, Vecchi and Añón (2009)
identified two tetrapeptides in the sequence of the 11S-glob,
namely VIKP and ALEP. These tetrapeptides displayed
inhibitory capacity on ACE. The analysis consisted of differentTABLE 1 | Sequences of bioactive peptides derived from Amaranth proteins with antihypertensive activity.
Sequence Level of evidenceof bioactivity Mechanismof action IC50/EC50 Reference
GKP Database search ACE
inhibitor








LPP, LRP, VPP, YP Identified in an active fraction ACE
inhibitor
Silva-Sánchez et al., 2008
ALEP Evaluated in silico and in vitro.
In bold peptide evaluated in vivo.
ACE
inhibitor
6.32 mM Vecchi and Añón, 2009
VIKP 0.175 mM
AY, FP, FY, GY, HY, IR, IY, LF, LW, LY,
MF, MY, PR, RF, RL, RY, VF, VW, VY,
YG, YL,YP, AAP, AIP, AVP, FNQ, FQP,
GGY, GKP, GRP, HIR, IKP, ILP, IRA,
LAA, LAY, LLP, LNP, LPP, LQP, LQQ,
LRP, LSP, LVL, LVR, PLP, PQR, PRY,
TAP, VAA, VAP, VAY, VLP,VPP,VRP,
VSP, VYP, ALPP, LAMA, YGGY
Identified in glutelin
hydrolysates.







Barba de la Rosa et al.,
2010




Identified in an active fraction. ACE
inhibitor
Vilcacundo et al., 2019
NIDMLRL, LVRW, VRWS, VR, CIHNIVY Identified in an active fraction. ACE
inhibitor
Ayala-Niño et al., 2019a
FNLPILR Identified in an active fraction.
Evaluated in silico and in vitro.
Renin
inhibitor
0.41 mM Quiroga et al., 2017
Nardo et al., 2020SFNLPILR 2.50 mM
AFEDGFEWVSKF 1.47 mMSeptember 2020 | Volume 11 | Article 578631
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11S globulin and then they examined the potential water
accessibility (accessible surface area, ASA) of each amino acid
residue and identified the encrypted antihypertensive peptides
according to the information of BIOPEP-UWM database.
Considering that the functionality of bioactive peptides
depends on their release from the mother sequence, Vecchi
and Añón (2009) identified two tripeptides, IKP and LEP with
high antihypertensive capacity. These peptides were located on
the surface of the protein molecule. From KP and EP, two
libraries were constructed by N-terminal extension using the
11S-glob primary sequence, employing ligand-protein docking
assay to simulate the ability of each member of the library to bind
the active site of ACE. Most of evaluated peptides were found to
be suitable ligands, displaying interaction energy values that were
comparable to that of control inhibitory peptides (KP, IKP, EP,Frontiers in Plant Science | www.frontiersin.org 5LEP and captopril). In all cases, the peptides interacted through
ionic bonds established with the free coordination sites of the
Zn++ of the active site. VIKP and ALEP were the peptides with
the highest potential antihypertensive activity, being their
theoretical interaction free energy of a magnitude comparable
to that of the parental peptide. Both peptides can also be found in
Glycine max glycinin and in the Chenopodium quinoa 11S-glob.
Vecchi and Añón (2009) confirmed the predicted results
obtained in silico by synthesizing the two tetrapeptides and
verifying their ACE inhibitory activity in vitro. Both ALEP and
VIKP presented inhibitory capacity, with IC50 values of 6.32 mM
and 175 µM, respectively (Table 1). The difference in the IC50
values could be attributed, at least partially, to the way in which
these peptides bind to the active site: VIKP interacts with the Zn++
ion via its C-terminal carboxyl moiety, while ALEP does so by
means of its glutamic acid R group, as shown in Figure 2A. ThisA
B
FIGURE 2 | Structures of Angiotensin Converting Enzyme, ACE (A) and Renin (B) with their catalytic residues marked in yellow (1A, B). Proposed complex for the
most potent inhibitor peptides identified in amaranth proteins for each enzyme (2A, B).September 2020 | Volume 11 | Article 578631
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for peptides with antihypertensive activity and to assess their ACE
inhibition capacity.
Quiroga et al. (2012) analyzed the potential bioactivity of the
7S globulin. These authors performed a theoretical search by
comparing the tryptic sequences of the 7S-glob subunits of 66,
52, 38, 35, and 16 kDa previously identified with the ACE
inhibitor sequences in the BIOPEP-UWM database. In all
subunits they found numerous di and tripeptides with
potential antihypertensive activity.
The use of bioinformatics tools has allowed demonstrating
that amaranth storage proteins and their constituent fractions
are potential sources of antihypertensive peptides and to identify
two tetrapeptides encrypted in the 11S-glob as competitive
ACE inhibitors.
In Vitro Assays
Tovar-Pérez et al. (2009) studied the ACE-inhibitory capacity of
the peptidic fraction obtained by alcalase hydrolysis of albumins
and globulins of A. hypochondriacus. The hydrolysis of albumin
and globulin, carried out for 15 and 18 h, respectively, yielded
different maximum degrees of hydrolysis, DH, 44 and 13%,
respectively. These hydrolysates showed a moderate ACE
inhibitory capacity. The greatest inhibition corresponded to the
globulin fraction (IC50 1.16 and 0.63 mg/ml, for albumins and
globulins, respectively), which agrees with the predictive analysis
performed by Rastogi and Shukla (2013). The hydrolysates were
subsequently purified by filtration gel chromatography and RP-
HPLC, obtaining fractions with an average size of 3–4 amino
acids and IC50 values of 0.35 and 0.15 mg/ml for albumins and
globulins, respectively.
By LC/MM/MM analysis of tryptic digests of the glutelin
fraction of A. hypochondriacus, Silva-Sánchez et al. (2008) also
detected the sequences LPP, LRP, VPP, and YP. Aoyagi (2006)
demonstrated that the same sequences from buckwheat, another
pseudocereal, presented ACE inhibitory activity in spontaneously
hypertensive rats.
Studies carried out with concentrates ofA. cruentus hydrolyzed
with alcalase have shown that the peptides obtained had ACE
inhibitory activity (IC50 0.176 ± 0.014 mg/ml) (Tiengo et al., 2009).
This capacity remained almost unaltered when the concentrates
were thermally treated before hydrolysis (EC50 0.138 ± 0.002 mg/
ml), suggesting that protein denaturation does not affect the
sensitivity to alcalase hydrolysis.
Fritz et al. (2011) used different proteases—pronase, papain,
trypsin, chymotrypsin and alcalase—and different assay
conditions to obtain hydrolysates from the protein isolate of A.
mantegazzianus. In most cases, the hydrolysates contained ACE
inhibitor peptides. However, the hydrolysate with the highest
activity was that obtained with alcalase (0.8 mg/ml - 4 h - 37 °C).
The degree of inhibitory activity obtained was proportional to
the degree of hydrolysis, suggesting a relationship between this
activity and peptide length. The IC50 values obtained in in vitro
assays for hydrolysates with 45 and 65% DH were 415 and 600
mM, respectively, the same order of magnitude than those usually
found for food protein hydrolysates. Fritz et al. (2011) stated thatFrontiers in Plant Science | www.frontiersin.org 6these IC50 values were similar to those obtained with the pure
antihypertensive inhibitors included in the BIOPEP-UWM
database at the time, suggesting the presence of peptides with
different inhibitory potency in the hydrolysate.
Ayala-Niño et al. (2019a) analyzed the profile of peptides
obtained by the consecutive hydrolysis of a protein isolate from
A. hypochondriacus with alcalase and flavourzyme. Their results
showed that action of both enzymes affords hydrolysates with
high antioxidant, antithrombotic and antihypertensive activity. It
should be noted that the values obtained by Ayala-Niño et al.
(2019a) are not very different from those reported by other
authors for hydrolysates with alcalase (Fritz et al., 2011; Ramıŕez-
Torres et al., 2017). The chromatographic fractionation of the
hydrolysates obtained with alcalase-flavourzyme rendered 14
fractions out of a total of 56, in which known proteins were
identified. The IC50 ranges for these fractions were similar to
those of hydrolysates obtained under other experimental
conditions. Finally, the sequence identification of the peptides
presents in two of these fractions was performed by MALDI-
TOF. This analysis allowed identifying novel peptide sequences
4–8 amino acids long, such as NIDMLRL, LVRW, VRWS, VR,
and CIHNIVY, containing amino acids and short sequences
whose ACE inhibitory capacity had been demonstrated in other
systems (Ueno et al., 2005; De Gobba et al., 2014; Aluko, 2015b;
Balgir and Sharma, 2017) (Table 1).
Taking into account these results and those obtained in other
food systems, it can be suggested that alcalase is the enzyme of
choice to release bioactive peptides from amaranth storage
proteins. Recently Ramıŕez-Torres et al. (2017) optimized the
process conditions using a commercial protein isolate as
substrate. To do this, authors used a response surface analysis
with 24 possible combinations of reaction conditions (pH,
reaction time, enzyme concentration, and temperature) and in
all cases ACE inhibitory capacity was evaluated. The results
obtained in those experiments indicated that the optimal
conditions for hydrolysis with alcalase were pH 7.01, 52°C,
enzyme concentration 0.04 mU/mg, and 6.16 h. The degree of
hydrolysis reached was 74.77% with a 93.5% of ACE inhibition.
Fermentation was also evaluated as a method to release of
bioactive peptides encrypted in amaranth storage proteins.
Ayala-Niño et al. (2019b) used Lactobacillus casei Shirota and
Streptococcus thermophilus 54102 in mono- and combined
culture as starters. The authors detected the release of
antihypertensive peptides (45% inhibition of ACE).
Unlike those discussed so far, Luna-Suárez et al. (2010) used an
alternative route to obtain an amaranth protein fraction, 11S-glob,
with increased antihypertensive activity. These authors used genetic
engineering tools to insert four VP sequences, of recognized
antihypertensive action, in tandem in the fourth variable region of
the molecule. The hydrolysates obtained by the action of trypsin-
chymotrypsin showed a higher activity, eight times higher, (IC50
0.06 mg/ml) than that corresponding to the hydrolysate obtained
from unmodified 11S-glob. The expression of this protein in E.coli
showed a high degree of insolubilization and the highest amount of
recombinant protein expressed was 60 mg/L. In order to improve
the functionality of this protein, a second modification wasSeptember 2020 | Volume 11 | Article 578631
Nardo et al. Amaranth Antihypertensive Peptidesintroduced in the C-terminal zone (Castro-Martıńez et al., 2012). In
this case, the maximum production of the recombinant protein
obtained was 99 mg/L and the IC50 of ACE inhibition of its
hydrolysate was 0.047 mg/ml.
Recently, Espinosa-Hernández et al. (2019) introduced a
modification in 11S-glob, adding four VY with antihypertensive
properties in the C-terminal region of the molecule. This new
protein has a higher level of expression in E.coli, presents better
structural stability and its trypsin hydrolysate, a better ACE
inhibitor potential (IC50 0.034 mg/ml). Although IC50 values for
ACE inhibition are higher than those indicated for peptides
obtained by hydrolysis of 11S globulin, glutelins, isolates or
concentrates, an in-depth analysis is required regarding costs,
preparation times, and possibilities of use in food.
The studies presented above show that the different protein
fractions that make up the storage proteins of the amaranth grain,
as well as derived protein products, isolates and protein
concentrates, have encrypted peptides with ACE inhibitory
activity in vitro. These results also indicate that proteases from
microorganisms can be used to release bioactive peptides.
These evidences, however, imply that neither the release of
these active peptides invariably occurs in vivo, nor that, in case
such release is feasible, the active peptides will be bioavailable to
exert their biological function.
Different studies have used a simulated gastrointestinal
digestion process to analyze the accessibility of ACE-inhibiting
amaranth peptides. Initially, simulation protocols involved the
sequential use of pepsin and trypsin, but the experimental
conditions varied among authors, which made the comparison
of results extremely difficult. Most of the research groups have
recently adopted the consensus protocol developed within the
framework of the INFOGEST Program (Minekus et al., 2014),
which will allow a better interpretation of the results obtained.
Tiengo et al. (2009) employed a hydrolysis protocol with
pepsin-trypsin to simulate the gastric digestion process of
unheated and heated concentrates of A. cruentus and its alcalase
hydrolysates. The highest values of IC50 were those obtained with
unheated and heated concentrates (0.439 ± 0.018 mg protein/ml
and 0.475 ± 0.021 mg protein/ml, respectively) and the lowest value
corresponded to alcalase hydrolysates, before and after a simulated
DGI (0.137 ± 0.002 mg protein/ml, and 0.176 ± 0.014 mg protein/
ml, respectively). Under those experimental conditions, the results
suggest that the degree of protein denaturation does not affect the
sensitivity to alcalase hydrolysis, that the peptides released by
alcalase are resistant to the action of the simulated gastrointestinal
digestion process and that the antihypertensive peptides can be
released during the DGI of amaranth concentrates, although with
reduced activity.
Only one study has demonstrated the ACE inhibitory
capacity of a partially purified 7S-glob subjected to a simulated
DGI, with this activity being similar to that of the 11S-glob
digests (EC50 0.17 ± 0.03 mg/ml and 0.17 ± 0.01mg/ml,
respectively) (Quiroga et al., 2012).
Aphalo et al. (2015) reported the ACE inhibitory activity of
amaranth sprouts and demonstrated that this activity increases
after a simulated DGI (IC50 0.26 ± 0.07 mg/ml).Frontiers in Plant Science | www.frontiersin.org 7Vilcacundo et al. (2019) have recently subjected a protein
concentrate of A. caudatus to a gastrointestinal digestion process
using the protocol published by Minekus et al. (2014) and
analyzed the potential multi-functionality of the released
peptides in each digestion stage. These authors evaluated the
antioxidant and the ACE inhibitory capacities, the viability of
colon cancer cells and the ability to inhibit DPP-IV, a-amylase.
The IC50 values for ACE inhibitory capacity were 79.13 ± 1.08,
39.00 ± 2.99, and 88.01 ± 13.96 µg/ml for the initial concentrate,
after gastric digestion and at the end of the process, respectively.
These results indicate that during the gastric stage, peptides with
greater inhibitory capacity are released; and that these peptides
would be sensitive to pancreatic enzymes. Vilcacundo et al.
(2019), compared their results with those obtained by Soriano-
Santos and Escalona-Buendıá (2015) with alcalase hydrolysates
of amaranth albumins and globulins and concluded that the
alcalase hydrolysis promoted the release of inhibitory peptides,
but to a lesser extent than the simulated digestion. Comparing
the results obtained by Vilcacundo et al. (2019) and Fritz et al.
(2011), is possible to infer that differences the ACE inhibitory
activity obtained in both studies are more similar, suggesting that
the inhibition values obtained depend not only on the type of
enzyme used but also on the experimental conditions. By LC/
MS/MS these authors identified the peptides released at the end
of the simulated DGI. These peptides, 13 sequences, consisted of
5–9 amino acids long sequences, which matched amaranth
proteins found in the database. Among the peptides released,
eight contained leucine, proline, valine, histidine, or
phenylalanine, which could be crucial to exert the ACE
inhibitory effect (Table 1).
These studies clearly demonstrate not only the existence of
amaranth peptides with the ability to inhibit ACE, but also that
many of these peptides are resistant to the hydrolytic action of
digestive enzymes.
In most of the in vitro studies performed the specific peptide/s
responsible for the activity is unknown and when putative
sequences were identified their activity was not experimentally
verified. Therefore, despite the relevant advances made in the last
ten years by different research groups, many aspects remain to
be clarified.
In Vivo Assays
The biological activity of peptides is dependent not only on their
accessibility, but also on their bioavailability. In this sense,
transport experiments must be carried out both in vitro and
in vivo.
Fritz et al. (2011) demonstrated for the first time the
antihypertensive capacity of protein hydrolysates of A.
hypocondriacus in vivo using spontaneously hypertensive
Wistar rats (SHR). The intragastric administration of alcalase
hydrolysates with 45% DH was effective in lowering blood
pressure values of SHR rats in a dose-dependent fashion. The
hypotensive effect was maximal 90 min after administration of
the hydrolysate and persisted for up to 7 h. In these experiments,
BP dropped from 140 to 100 mmHg. These results support an
action of the amaranth peptides on the vascular peripheralSeptember 2020 | Volume 11 | Article 578631
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vitro. In order to rule out a possible effect of amaranth peptides
on the myocardium, which would affect the cardiac output, Fritz
et al. (2011) carried out experiments on papillary muscles
isolated from SHR. In these experiments, authors were not able
to detect any significant negative inotropic effect. These authors
also performed ex vivo experiments performed on isolated aortic
rings have shown that the contraction induced by
norepinephrine (10-8 M – 10-4 M) is antagonized by amaranth
peptides (0.1 g/ml), suggesting a vasodilator effect. These results
would support the idea that the amaranth peptides present in the
hydrolysate would induce the reduction of BP by decreasing the
vascular peripheral resistance, even in isolated systems such as
the aorta, suggesting that the hydrolysate would exert its effect on
both the local and tissue RAAS.
Lado et al. (2015) corroborated the antihypertensive effect of
amaranth proteins/peptides in vivo. These authors reported that
normotensive Wistar rats fed for 4 weeks with a normal diet for
laboratory rodents (AIN93), in which 12.5% of casein had been
replaced by amaranth protein isolate, experienced a reduction in
their BP of 27 mmHg, as compared to the control group fed only
with casein as a protein source.
Ramıŕez-Torres et al. (2017) analyzed the bioavailability of
alcalase amaranth protein hydrolysates in BALB/c mice. Three
groups of animals received intragastric water, captopril (25 mg/
kg animal) and the amaranth hydrolysate (2.4 g/kg animal),
respectively. Blood samples were then collected from the tail vein
(5–60 min) and indirectly determined the presence in the serum
of amaranth peptides with ACE inhibitory activity. After 5 and
10 min, the groups administered with captopril and the
hydrolysate showed a high percentage of ACE inhibition
(approximately 50 and 30% inhibition, respectively), and this
inhibition was maintained for approximately 60 min.
Throughout the experiment, the group that received water
showed an ACE inhibition equal to or less than 10%. After
120 min, all the animals presented very low and similar
inhibition values. SHR rats, which received the same treatment
as BALB/c mice, were used to determine systolic BP values. The
animals’ systolic BP (approx. 180 mmHg) began to decrease atFrontiers in Plant Science | www.frontiersin.org 83 h after the administration of either captopril of the hydrolysate,
reaching the lowest value after 5 h (110 and 140 mmHg for
animals treated with captopril or the hydrolysate, respectively).
Suárez et al. (2020) have recently demonstrated that different
products derived from amaranth, a protein isolate, an alcalase
hydrolysate, VIKP (a peptide with proven antihypertensive
activity, or an oil-water emulsion formulated with isolate-
hydrolyzed amaranth as a surfactant with and without the
addition of VIKP), have antihypertensive activity in SHR. It
should be noted that the amount of sample supplied to the
animals was 38 times lower in the case of VIKP (50 mg/Kg rat vs
1.9 g protein/Kg rat). The results obtained in these experiments
indicate that the administration of amaranth-based emulsions,
either with and without the addition of VIKP, cause a reduction
in the systolic BP of about 42 and 35 mmHg. This reduction of
BP was equal to or greater than that induced by captopril (35
mmHg), a recognized ACE inhibitor. The rest of the samples
tested induced a drop in systolic BP of 26–21 mmHg, showing
that VIKP is capable of reducing BP to a much lower
concentration than API and APH. All the samples tested, like
captopril, induced an increase in the amount of circulating ACE,
whose activity was inversely proportional to its concentration.
This suggests a greater release of ACE to the circulatory system
but with minimal activity. These authors also determined the
contractile activity of thoracic aorta rings in the presence of
potassium ions and norepinephrine. These compounds are
known to cause vasoconstriction through the action on
voltage- and receptor-operated channels, respectively. In the
presence of potassium, the contractile activity of the aorta
rings from the animals treated with all the samples was lower,
while in the presence of norepinephrine, less activity was
detected only in the aortas from animals administered with
VIKP dissolved in water or added to the emulsion made from
amaranth. It is noteworthy that no reduction in the contractile
activity was detected in animals treated with captopril, a
competitive ACE inhibitor. Figure 3 shows the contractile
intensity of isolated aortic rings contracted by exposure to
potassium (Figure 3A) and norepinephrine (Figure 3B).
According to these results, the amaranth peptides releasedA B
FIGURE 3 | Effect of different samples on contractile activity of isolated aortic rings as the strength per weight of the ring (gF/mg) contracted by exposure to
potassium (A) and norepinephrine (B). Rings extracted from animals treated with emulsion added with VIKP (E+VIKP), captopril (CC) aliskiren (CA) and water (CW).September 2020 | Volume 11 | Article 578631
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resistant to such process would not only inhibit ACE but
would also act on the local RAAS system, affecting the polarity
of the membrane and, possibly in the case of VIKP, interacting
with adrenergic receptors.
The results discussed so far strongly suggest that the
amaranth peptides and/or products thereof generated in the
gastrointestinal digestion process are bioavailable and exert a
marked reduction in blood pressure in hypertensive animals.
NOs Peptides
As mentioned, ACE is an enzyme capable of interacting with a
variety of substrates, such as Ang I and bradykinin, among
others. Bradykinin (RPPGFSPFR) has a potent vasodilator and
inflammatory action. It is capable of binding to two receptors,
BK-B1 and BK-B2, belonging to the G protein coupled receptor
(GPCR) family. Its binding to the B2 receptor induces an
increase in intracellular Ca++ in the endothelium and activates
one of the isoforms of nitric oxide oxidase (eNOs). In the
presence of oxygen, this enzyme transforms arginine into
citrulline and NO, which acts on the smooth muscle
stimulating the guanylate cyclase, the enzyme responsible for
transformation of GTP into GMPC, which is a mediator with
vasodilator properties. GMPC is in turn transformed into GMP
and pyrophosphate by the action of GMP phosphodiesterase.
NO is also activated by acetylcholine and growth factors like the
vascular endothelial growth factor (Förstermann and Li, 2011).
Barba de la Rosa et al. (2010) analyzed the capacity of peptides
encrypted in the sequence of glutelins released by the action of
trypsin to inhibit ACE and the production of NO. These authors
identified more than 60 peptides in the hydrolysate, mostly tri and
dipeptides, some of which with recognized antihypertensive
activity (YP, LPP, LRP and VPP). The hydrolysate presented an
IC50 value of 200 µg/ml for ACE inhibition (Table 1). Authors
hypothesized that the inhibition of ACE would lead to an increase
in bradykinin levels and therefore the hydrolysate obtained could
induce an increase in NO production. Their results showed that
both the hydrolysate obtained and the intact glutelins induced NO
production, with the increase induced by the hydrolysate being of
a greater magnitude (97 µM and 75 µM for 100 µg/ml of sample,
respectively). In order to determine if the hydrolysate was able to
stimulate NO production through activation of eNOS, rat
coronary endothelium cells were incubated with either
bradykinin, a bradykinin receptor inhibitor (HOE-140) and the
hydrolysate. They observed that both bradykinin and the
hydrolysate stimulated NO production and that this production
was totally inhibited by HOE-140 in the case of bradykinin and
only partially inhibited in the case of the hydrolysate. Thus, the
eNOs activity induced by hydrolysate is mediated, in part, by the
BK-B2 receptor; and the participation of other signaling pathways
in control of vascular activity cannot be ruled out. To corroborate
the NO production, the authors examined the capacity of
hydrolysate to induce vasorelaxation of aortic rings. The
hydrolysate induced vasorelaxation of rings in a dose-dependent
manner, an effect that was partially blocked when the endothelium
was removed from the vessel. The hydrolysate-inducedFrontiers in Plant Science | www.frontiersin.org 9vasorelaxant effect was totally inhibited when the rings were
pretreated with HOE-140, suggesting a central role for bradykinin.
Fritz et al. (2011) also performed ex vivo experiments using
aortic smooth muscle rings as discussed above. The exposure of
aortic rings to the amaranth hydrolysate previously contracted with
norepinephrine causes a significant decrease in the contractile
response. These authors reported that the preincubation of aortic
rings with 100mMN(w)-nitro-L-arginine methyl ester, L-NAME, a
widely used eNOs inhibitor, did not cause any change in the
response. This suggests that the vasorelaxant effect observed with
the peptides derived from the globulin fraction present in the
hydrolysate would not be associated with the production of NO.
Renin Inhibitory Peptides
Renin (EC3.4.23.15) is a 37kDa endo aspartyl protease that belongs
to peptidase A1 family that is secreted by the kidney into the
bloodstream (Inagami, 1981; Yuan et al., 2006; Pihlanto and
Mäkinen, 2017; Aluko, 2019). The most important structural
feature of renin is the antiparallel beta sheet that forms two
similar lobes/domains with a cleft between them. The active site is
located in the cleft and substrate recognition site consists of 5
pockets, namely S1, S2, S3, S1′ and S2′, and a subpocket termed S3SP
(Rahuel et al., 2000). Its active site contains twoAsp that are used to
cleanse the substrate through an acid-base hydrolysis mechanism.
Quiroga et al. (2017) studied for first time the capacity of
amaranth peptides to inhibit renin, the first enzyme of the RAAS
system. The authors obtained alcalase hydrolysates from protein
isolates of A. hypocondriacus with an average peptide length of
4–6 amino acids (HD 21%) and a molecular mass range of 1.355
and 0.179 kDa corresponding to 12 amino acid long peptides and
free amino acids. These peptides were able to inhibit renin,
reaching 60% inhibitory capacity and an IC50 of 0.6 mg/ml.
These values were similar to those reported in the literature for
peptides of other origins (Fitzgerald et al., 2012; He et al., 2013).
Although the protein isolate was able to inhibit renin, its
inhibitory capacity was more than 20 times lower than the
hydrolysate, which again highlights the need to release
encrypted peptides with greater potency than their original
proteins. The hydrolysate exhibited a renin competitive
inhibition behavior, with a Ki value of 0.25 mg/ml, which was
lower than that obtained for the hemp seed hydrolysate (Girgih
et al., 2011). Peptidic renin inhibitors from other origins have
shown competitive, uncompetitive, non-competitive, and mixed
inhibition mechanisms, implying the existence of binding sites
other than the active site. These interactions modify the affinity
of the active site for the substrate. Quiroga et al. (2017) also
fractionated the isolate by molecular exclusion chromatography
and then by RP-HPLC. The results achieved showed that the
inhibitory activity was directly related to the hydrophobicity of
the peptides. The most active fraction showed an inhibition of
67 ± 5%/mg of peptide. In this fraction, six peptides were
ident ified : QAFEDGFEWVSKF, AFEDGFEWVSKF,
SFNLPILR, FNLPILR, SFNLPIL, VNVDDPSKA containing
almost the same amount of hydrophobic amino acids (about
43%), and hydrophilic (about 47%), the remaining 10% of total
amino acids was P and G.September 2020 | Volume 11 | Article 578631
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interaction of the aforementioned peptides with renin. Initially,
they used the CABS-dock server to perform a global docking assay
on the enzyme surface, to obtain the renin-peptide complexes and
to analyze the residues involved in the interaction. For each
evaluated peptide, 10 models were generated which were
analyzed. The authors found that the 6 peptides analyzed were
capable of binding to different sites of the enzyme, including the
active site, and that there were certain residues of the renin
sequence that participated more frequently in the interaction,
suggesting the presence of protein-protein recognition motifs
located on the renin surface. Using the FlexPepDock server, they
performed a local docking experiment and estimated the energies
of the peptide-renin interaction only in the cases in which the
peptide interacted with the active site of the enzyme (Figure 2B).
The best interaction energies were achieved with the peptides
AFEDGFEWVSKF and SFNLPILR. In order to validate the results
achieved in silico, the authors carried out the chemical synthesis of
these two peptides, as well as FNLPILR and VNVDDPSKA, and
determined their renin inhibitory capacity in vitro. FNLPILR was
the most potent inhibitor, with an IC50 value of 0.41 mM, and
VNVDDPSKA was not able to inhibit the enzyme at any
concentration in the range used by the authors. SFNLPILR and
AFEDGFEWVSKF also showed a lower inhibitory activity, with
IC50 values of 2.50 and 1.47 mM, respectively. These results did
not totally agree with score values obtained with FlexPepDock,
which predicted a higher affinity for SFNLPILR followed by
AFEDGFEWVSKF and FNLPILR. Nardo et al. (2020) stated
that these inconsistencies had already been reported by other
authors, attributing the problem to the scoring function of the
docking technique using peptides as ligands.
As the hydrolysate, FNLPILR acted as a competitive inhibitor.
Moreover, the six peptides interacted with the renin active site in
different ways. For example, SFNLPILR orients its N-terminal
towards catalytic residues, while AFEDGFEWVSKF peptide
interacts with the active site through the R residue located at
its C-terminal. The latter peptide was found to establish two
hydrogen bonds, and one p-interaction with renin residues.
SFNLPILR interacts by SF motif, FNLPILR do it by LR motif.
Given that renin is the first enzyme in the RAAS system and
that it is only capable of hydrolyzing angiotensinogen, its
inhibition is key in the regulation of BP.
Unlike ACE, studies related to the inhibition renin are scarce,
both in amaranth and in other food systems. Finally, the inhibition of
renin could be another mechanism of action of amaranth peptides.FUNCTIONAL FOODS
The existence of peptides encrypted in the food protein sequence
bearing a variety of physiological activities opens up a very
interesting possibility for the production of novel functional
foods. On the other hand, this possibility presents new
challenges related to the modifications that the elaboration
processes can exert on such biological activities, as well as theFrontiers in Plant Science | www.frontiersin.org 10presence of different components that can act as either activators
or antagonists of the bioactive components.
Suárez and Añón (2019) have assessed two types of properties of
amaranth proteins: their techno-functional properties and the
presence of physiologically active sequences in their structure. The
objective of their study was to elaborate 20:80 O:W emulsions
formulated with equal amounts of protein isolates of A.
hypochondriacus (API), and an alcalase hydrolysate (APH) (1–2%
protein API50:APH50) as surfactants and carriers of bioactive
peptides. The authors obtained highly flocculated emulsions that
were stable upon creaming and coalescence for at least 8 days.
According these authors, the peptides present in the hydrolysate
could form part of the interfacial film and/or the floc network
present in the continuous phase of the emulsion. The emulsions
formulated with API were subjected to a simulated gastrointestinal
digestion process. The results obtained showed an important
stability of the emulsion during the gastric stage and the
appearance of aggregation and coalescence phenomena in
duodenal stage. In the digestive stage, a rapid release of fatty acids
of the order of 29% was also detected, without any induction stage.
This relatively low value was probably due to the accumulation of
lipolysis products on the droplet surface, thus reducing enzymatic
activity. The behavior of the API50:APH50 emulsion during the
simulated gastrointestinal digestion process was similar to that
described for API emulsions. Finally, these authors verified that
the emulsions formulated before and after being subjected to the
gastrointestinal digestion process had a dose-dependent ACE
inhibitory effect (IC50 0.29 ± 0.03 and 0.14 ± 0.02 mg/ml,
respectively). The bioactive peptides responsible for this activity
can be peptides present in the API andAPHused in the formulation
of the emulsion, which were not affected by the gastrointestinal
enzymes and/or new peptides generated by the action of those
enzymes from the same substrates. This type of bioactive emulsion
displaying antihypertensive properties opens possibilities for the
formulation of functional foods, such as dressings. Previously it was
discussed that Suárez et al. (2020) have shown that these emulsions
administered to Wistar SHR reduce their BP to normal values.
Valdez-Meza et al. (2019) have elaborated pastes, modifying
the protein content by partial replacement of semolina by
variable amounts of an amaranth protein concentrate and a
constant amount of amaranth protein hydrolysate (IC50 0.014
mg/ml). The control containing semolina had 11% protein, while
the amaranth formulations, 15 and 20%. The addition of
amaranth reduced cooking time and losses of pasta; increased
its firmness and reduced the adhesiveness. Supplemented pastes,
in turn, were less luminous and presented a more intense brown
color than the control. On the other hand, amaranth
supplementation negatively impacted the total acceptability of
the products and the taste. The ingestion of the 8 g of cooked
supplemented pasta decreased significantly systolic blood
pressure of SHR Wistar rats after 3 h of ingestion, as
compared to controls, and this effect was sustained for about
7–8 h. The authors attribute the antihypertensive effect of the
product mainly to the addition of the hydrolysate to the matrix.
Since supplemented pastes contain a significant amount ofSeptember 2020 | Volume 11 | Article 578631
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other components could contribute to the result achieved.
Sabbione et al. (2018)\ formulated amaranth flour cookies that
are suitable for vegan and gluten-free diets and with adequate
physicochemical and sensory characteristics. The cookies provide
114 Kcal per 30 g serving. The cookies and flour used were subjected
to a simulated gastrointestinal digestion process, reaching 38 and
41% DH, respectively. The digests obtained displayed a dose-
dependent ACE inhibitory activity in vitro. The IC50 values were
0.23 ± 0.03 and 0.08 ± 0.01 mg/ml for cookies and flour,
respectively. Different IC50 values obtained for both samples could
be attributed to the release of different peptides during simulated
GID. Since the nature of proteins is the same in flour and cookies,
the presence, in the latter, of a matrix and other components could
modify the action of the different enzymes that act in the
digestion process.
Ontiveros et al. (2020) formulated wheat flour cookies in
which 10% of the wheat flour was replaced by a amaranth
alcalase hydrolysate with proven hypertensive properties both
in vitro and in vivo (Ramıŕez-Torres et al., 2017). Authors
obtained cookies with adequate characteristics, which were
administered to BALB/c mice and SHR rats in order to
determine the bioavailability of the bioactive peptides and their
action on the blood pressure. Their results showed that after
5 min of ingestion, the compounds reach the plasma and have an
inhibitory activity on ACE that lasts 2 h. In addition, the intake
of cookies causes a reduction of blood pressure after 3 h of
ingestion, to reach a level similar to that achieved with captopril.
This effect was maintained for up to 6 h after ingestion.
The results achieved so far show that the inhibitory potency of
peptides studied is much lower than that of classical drugs such as
captopril. Therefore, it is necessary much higher amounts of
amaranth proteins than drug, to achieve an in vivo BP reduction
equivalent to captopril. This is valid not only for amaranth peptides
but also for peptides from animal and vegetable sources. Inmost of
the in vivo tests performed the amount of protein given to the
animals, either asflour,API, APH, emulsions, cookies or pastaswas
approximately 1.9–1.2 g/kg rat in a single intake, 38–25 timesmore
than the unique peptide assayed (VIKP, 50 mg/kg rat) and 76–48
timesmore than the captopril dose administered (25mg/kg rat). In
order to have an approximation of the amount of amaranth protein
that a human should consume we have used the human equivalent
dose calculation (Center for Drug Evaluation and Research, 2005).
According with these data 1.9–1.2 g/kg rat, would be equivalent to
0.30–0.19 g/kg humans. Considering the amount of protein present
in the different protein sources this value is equivalent to,
approximately 1.5–1.0 g of grains or flours, 0.47–0.3 g of API and
0.66–0.42 g of APH by kg human. These values must be
transformed into quantity of food that will depend on their
protein content.
It is evident that the presence of amaranth proteins added as
flour, protein concentrates and isolates and hydrolyzed in different
food matrices, allows obtaining different functional foods with
antihypertensive activity. The combined use of bioactive and
techno-functional properties of amaranth proteins open up very
interesting perspectives for the development of novel products.Frontiers in Plant Science | www.frontiersin.org 11CONCLUSIONS
The results depicted above showed that amaranth is a natural source
of peptides and protein hydrolysates with antihypertensive activity,
whose target can be located at the level of circulating and local
RAAS. The main objective of the study of these peptides is to use
them as an alternative to drugs and/or functional foods to reduce
the risk of developing hypertension and/or complement
conventional therapies.
In the case of amaranth peptides, to achieve this objective
there are still studies related to the standardization of methods
for obtaining the peptides, determination of the absorption
mechanisms and identification of markers to track the peptide
or its metabolites in animal models and/or humans. Moreover,
further studies related to the signaling mechanisms that trigger
these peptides, as well as clinical trials should be conducted to
verify their health benefits. The usefulness of bioinformatics and
computer tools should also be considered. More extensive
molecular dynamics simulations are required to analyze, at the
atomic level, the peptide-enzyme active site or peptide-receptor
interactions. Likewise, the use of new algorithms based on
technology such as machine learning can be extremely useful
to identify new peptides from complex mixtures.
It is unlikely that antihypertensive peptides will replace
conventional drugs in a short time, therefore the study and
development of novel and attractive functional foods is of utmost
importance. In the development of this type of food, the techno-
functional properties of amaranth proteins should be taken into
account, as well as the possible existence of peptides with more
than one physiological activity or mechanism of action.
In addition, considering the more recent achievements related
to the classical and local RAAS new studies should be focused in
the natriuretic and vasodilator action that opposes the damaging
effects of AngII. It is necessary to search for new peptides and/or
to analyze the action of already identified peptides on the newer
components of the RAAS system. The effect of peptides on the
up-regulation of ACE2, blocking the AT1 receptor or the activity
of peptidases that mediate the transformation of AngII into
AngIII would be relevant to study (Figure 1).
Finally, a more holistic look should be taken on the blood
pressure control system and consider the possible action of
antihypertensive peptides on the levels of oxidative stress,
inflammation, and prothrombotic effect.
In summary, to consider a food as functional and to be able to
make a health claim on its label, many multidisciplinary studies are
required. Particularly in the case of amaranth antihypertensive
peptides, although clinical trials have yet to be conducted, large
and promising advances have been made demonstrating that
amaranth proteins are sources of antihypertensive peptides.AUTHOR CONTRIBUTIONS
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amaranth glutelin digests induce endothelial nitric oxide production through
inhibition of ACE: Antihypertensive role of amaranth peptides. Nitric. Oxide -
Biol. Chem. 23, 106–111. doi: 10.1016/j.niox.2010.04.006
Barrio, D. A., and Añón, M. C. (2010). Potential antitumor properties of a protein
isolate obtained from the seeds of Amaranthus mantegazzianus. Eur. J. Nutr.
49, 73–82. doi: 10.1007/s00394-009-0051-9
Bejarano-Luján, D. L., Lopes da Cunha, R., and Netto, F. M. (2010). Structural and
rheological properties of amaranth protein concentrate gels obtained by different
processes. Food Hydrocoll. 24, 602–610. doi: 10.1016/j.foodhyd.2010.02.007
Bernstein, K. E., Ong, F. S., Blackwell, W. L. B., Shah, K. H., Giani, J. F., Gonzalez-
Villalobos, R. A., et al. (2013). A modern understanding of the traditional andnontraditional biological functions of angiotensin-converting enzyme.
Pharmacol. Rev. 65, 1–46. doi: 10.1124/pr.112.006809
Bolontrade, A. J., Scilingo, A. A., and Añón, M. C. (2013). Amaranth proteins
foaming properties: Adsorption kinetics and foam formation-Part 1. Colloids
Surf. B Biointerf. 105, 319–327. doi: 10.1016/j.colsurfb.2012.12.039
Bolontrade, A. J., Scilingo, A. A., and Añón, M. C. (2016). Amaranth proteins
foaming properties: Film rheology and foam stability - Part 2. Colloids Surf. B
Biointerf. 141, 643–650. doi: 10.1016/j.colsurfb.2014.10.061
Borghi, C., and Cicero, A. F. G. (2017). Nutraceuticals with a clinically detectable blood
pressure-lowering effect: a review of available randomized clinical trials and their
meta-analyses. Br. J. Clin. Pharmacol. 83, 163–171. doi: 10.1111/bcp.12902
Bressani, R. (1994). “Composition and Nutritional Properties of Amaranth,” in
Amarantha: biology, chemistry, and technology. Ed. O. Paredes-López (Boca
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Castellani, O. F., Martıńez, E. N., and Añón, M. C. (2000). Amaranth globulin
structure modifications induced by enzymatic proteolysis. J. Agric. Food Chem.
48, 5624–5629. doi: 10.1021/jf000624o
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Suárez, S., Aphalo, P., Rinaldi, G., Cristina, M., and Quiroga, A. (2020). Effect of
amaranth proteins on the RAS system. In vitro, in vivo and ex vivo assays. Food
Chem. 308, 125601. doi: 10.1016/j.foodchem.2019.125601
Tandang-Silvas, M. R., Cabanos, C. S., Carrazco Peña, L. D., De La Rosa, A. P. B.,
Osuna-Castro, J. A., Utsumi, S., et al. (2012). Crystal structure of a major seed
storage protein, 11S proglobulin, from Amaranthus hypochondriacus: Insight
into its physico-chemical properties. Food Chem. 135, 819–826. doi: 10.1016/
j.foodchem.2012.04.135
Tapia-Blácido, D. R., Sobral, P. J. A., and Menegalli, F. C. (2013). Effect of drying
conditions and plasticizer type on some physical and mechanical properties of
amaranth flour films. LWT - Food Sci. Technol. 50, 392–400. doi: 10.1016/
j.lwt.2012.09.008
Tiengo, A., Faria, M., and Netto, F. M. (2009). Characterization and ACE-
inhibitory activity of Amaranth proteins. J. Food Sci. 74, H121–H126.
doi: 10.1111/j.1750-3841.2009.01145.x
Touyz, R. M., and Schiffrin, E. L. (2000). Signal transduction mechanisms
mediating the physiological and pathophysiological actions of angiotensin II
in vascular smooth muscle cells. Pharmacol. Rev. 52, 639–672.
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